Table 2.
Adverse events
| Adverse events | Enco/Cetux/Bini (N = 36) |
Enco/Cetux (N = 97) |
P | Enco/Cetux/Bini (N = 36) |
Enco/Cetux (N = 97) |
P |
|---|---|---|---|---|---|---|
| Any grade, n (%) | Any grade, n (%) | Grade 3-4, n (%) | Grade 3-4, n (%) | |||
| Any adverse event | 35 (97) | 89 (92) | 0.44 | 12 (33) | 20 (21) | 0.20 |
| Asthenia | 23 (64) | 59 (61) | 0.90 | 3 (8) | 9 (9) | >0.99 |
| Anti-EGFR skin rash | 24 (66) | 45 (46) | 0.06 | 1 (3) | 2 (2) | >0.99 |
| Nausea | 19 (53) | 29 (30) | 0.03 | 3 (8) | 1 (1) | 0.06 |
| Diarrhea | 14 (39) | 21 (22) | 0.07 | 1 (3) | 2 (2) | >0.99 |
| Decreased appetite | 6 (17) | 28 (29) | 0.20 | 2 (6) | 3 (3) | 0.61 |
| Vomiting | 11 (31) | 13 (13) | 0.04 | 1 (3) | 1 (1) | 0.47 |
| Melanocytic nevus or skin lesions | 5 (14) | 29 (30) | 0.06 | 0 | 0 | — |
| Bowel obstruction | 2 (6) | 5 (5) | >0.99 | 1 (3) | 3 (3) | >0.99 |
| Anemia | 13 (36) | 30 (31) | 0.72 | 5 (14) | 5 (5) | 0.13 |
| Transaminase increase | 3 (8) | 12 (12) | 0.76 | 2 (6) | 0 | 0.07 |
| Creatinine increase | 5 (14) | 2 (2) | 0.02 | 0 | 1 (1) | >0.99 |
| Arthralgia | 3 (8) | 21 (22) | 0.13 | 0 | 2 (2) | >0.99 |
| Ocular toxicity | 0 | 1 (1) | >0.99 | 0 | 0 | — |
Bold/italic are statistically significant P values.
Bini, binimetinib; Cetux, cetuximab; EGFR, endothelial growth factor receptor; Enco, encorafenib; N, number; —, test not done.